ALS neuroprotectant series

ALSNot analyzed

Riluzole and edaravone chemotypes used in amyotrophic lateral sclerosis.

Mechanism · ALS BioMoa · ALS / CNS BioMoa bridge · shared ID

No analysis recorded yet · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · ClinicalTrials.gov · FDA/EMA · FDA · FDA (withdrawn)
Last updated: Not recorded
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 4
Exploratory nodes: 2
Abstract scaffolds: 1
Relationship types: Derived (curated) · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
Aminobenzothiazole coreAbstract pharmacophoreals-aminothiazole-corePage	Scaffold	`Nc1nc2ccccc2s1`	—	—	ALS · core · Shared pharmacophore / core scaffold. Anchor for the ALS neuroprotectant series lineage.
Edaravone (Radicava)Verified drugedaravonePage	Drug	`Cc1cc(=O)n(-c2ccccc2)n1`	Aminobenzothiazole core	—	ALS · FDA · approved · radical scavenger · Approved therapeutic. Edaravone (Radicava) in this family map.
Riluzole (Rilutek)Verified drugriluzolePage	Drug	`Nc1nc2cc(OC(F)(F)F)ccc2s1`	Aminobenzothiazole core	—	ALS · FDA · approved · glutamate · Approved therapeutic. Riluzole (Rilutek) in this family map.
Sodium phenylbutyrate (Relyvrio component)Verified drugphenylbutyratePage	Drug	`C1=CC=C(C=C1)CCCC(=O)O`	Aminobenzothiazole core	—	ALS · FDA · approved · histone deacetylase · Approved therapeutic. Sodium phenylbutyrate (Relyvrio component) in this family map.
Taurursodiol (Relyvrio component)Verified drugtaurursodiolPage	Drug	`CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(C…`	Aminobenzothiazole core	—	ALS · FDA · approved · bile acid · Approved therapeutic. Taurursodiol (Relyvrio component) in this family map.
Des-trifluoromethoxy riluzole analogExploratory analog (rule-generated)riluzole-des-trifluoromethoxyPage	Derivative	`Nc1nc2ccc(F)cc2s1`	Aminobenzothiazole core	—	SAR · SAR exploration node. Derived analog of parent node in ALS neuroprotectant series.
Edaravone methyl-walk analogExploratory analog (rule-generated)edaravone-methyl-walkPage	Derivative	`CCc1cc(=O)n(-c2ccccc2)n1`	Aminobenzothiazole core	—	SAR · SAR exploration node. Derived analog of parent node in ALS neuroprotectant series.

From the core chemical, derivatives, drugs, and payloads fan out. Dashed orange chords are drug–drug links (spider web).

Loading map…

Clinical · regulatory context

ALS — 소수 승인 + 실패 이력

Riluzole·edaravone이 승인 축. Relyvrio(AMX0035)는 승인 후 철회 이력이 있어 구조 이웃을 볼 때 규제 맥락이 중요합니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

RiluzoleApprovedFDA/EMA
ALS — survival modest benefit
ClinicalTrials.gov
EdaravoneApprovedFDA
ALS — functional decline slowing
ClinicalTrials.gov
Sodium phenylbutyrate (+ taurursodiol)WithdrawnFDA (withdrawn)
ALS (Relyvrio) — confirmatory failure → withdrawal
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · cns · StructureMoa ↔ BioMoa bridge